Opus Genetics Names New Chief Scientific Officer
The North Carolina biotech firm added Andrew Murphy and Jamie Lynne Hart to its executive leadership team.
Updated on Oct. 29, 2026 in Biotech
Live Poll
Do you trust that new leadership at medical companies leads to better results for patients?
Opus Genetics has appointed Andrew Murphy as its Chief Scientific Officer and Jamie Lynne Hart as the Executive Director of Executive Operations. These leadership changes are intended to bolster the company's clinical pipeline for inherited retinal diseases.
Why it matters
The appointments aim to strengthen the scientific leadership and operational capabilities of the North Carolina firm as it enters its next phase of growth. This expansion supports the advancement of the company's clinical gene therapy programs.
Dr. Andrew Murphy brings 18 years of biotechnology experience to the Research Triangle Park headquarters. Jamie Lynne Hart contributes 15 years of industry and ophthalmology expertise to support the firm's AAV-based gene therapy programs.
The players
Andrew Murphy
He is the new Chief Scientific Officer of Opus Genetics and holds a Ph.D. in Chemistry from Stanford University.
Jamie Lynne Hart
She is the newly appointed Executive Director of Executive Operations at Opus Genetics.
Opus Genetics
Based in Research Triangle Park, this biotechnology company focuses on developing gene therapies for inherited retinal diseases.
The details
The firm recruited these executives to enhance its research capacity and operational infrastructure in North Carolina. Dr. Murphy previously held a senior role at Kriya Therapeutics, while Hart served as Chief of Staff to the CEO at Apellis Pharmaceuticals.
Timeline
October 29, 2026: Opus Genetics announced the new executive appointments.
The Tech Race
These executive appointments reflect a broader effort to scale operational capacity in the highly competitive gene therapy sector. The expansion of leadership at Opus Genetics positions the firm to advance its clinical gene therapy pipeline against other emerging biotech rivals.
The strengthening of executive leadership could accelerate the timeline for bringing new gene therapies to patients with inherited retinal diseases. For the broader industry, these moves signal a maturing of the company's internal research and operations capabilities.
The takeaway
This leadership expansion highlights the ongoing need for experienced executives to navigate the complex clinical development process. The focus on retinal diseases demonstrates a specialized strategy within the broader gene therapy field.
Further reading
Learn more about the latest industry developments at Biotech.
More information
Read more about the company's clinical programs on the Opus Genetics company website.
Source note: This article includes information reported by The Manila times.
Live Poll
Do you trust that new leadership at medical companies leads to better results for patients?
